General information
Bayer AG
Kaiser-Wilhelm-Allee 1
Building W11
51368 Leverkusen, North Rhine-Westphalia
Germany
Contact person: Thomas Kornek, Vice President Investor Relations
Company main phone: +49 (214) 301
Website: https://www.bayer.com/
| Year founded: | 1863
|
| Source of foundation: | Independent foundation |
| Name of foundation source: | Founded by Friedrich Bayer and Johann Friedrich Weskott. |
| No. of employees: |
Worldwide: 87280 |
Corporate description / mission:
Bayer is a global life science company focusing on healthcare and nutrition. The company operates through three segments: crop science, pharmaceuticals, and consumer health. The Crop Science segment engages in the development, production, and marketing of seeds, plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The pharmaceuticals segment provides prescription products primarily for cardiology and women's health, specialty therapeutics in the areas of oncology, hematology, and ophthalmology, as well as diagnostic imaging equipment and contrast agents. The consumer health segment offers nonprescription over-the-counter medicines, medical products, cosmetics, and other self-care solutions in the categories of dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cough and cold.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1988
Categorization
| Sector: |
- Pharma (fully integrated)
|
| Subsector: |
- Cell therapy
- Drug delivery
- Proteins
- Small molecule therapeutics
- Other
|
| Primary therapeutic areas: |
- Cardiovascular / cardiology
- Conditions originating in the perinatal period / pediatrics
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the eye / ophthalmology
- Diseases of the nervous system / neurology
- Endocrine, nutritional and metabolic diseases / endocrinology
- Genitourinary system / Urology
- Mental and behavioural disorders / psychiatry /psychology
- Musculoskeletal system and connective tissue / Orthopedics
- Neoplasms / cancer / oncology
- Respiratory / pulmonology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
| Business model: |
- In-licensing
- Manufacturer
- Out-licensing
- R&D
- Supplier / Distributor
|
| Customer segments: |
- Consumers (mass market)
- Hospitals
- Physicians / doctors
|
| Distribution: |
- Direct (own sales force)
- Indirect (independent dealer)
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 4 | |
| Phase I: | 31 | |
| Phase II: | 14 | |
| Phase III: | 19 | |
| On the market: | 23 | |
Number of Medtech Products
| In development: | 2 | |
| On the market: | 2 | |
Description of products:
Nubeqa
AB-1005
Elinzanetant
Kerendia, etc.
Financing details
Fiscal year (end of) 2025
| Revenues: | USD 53'395.67M | |
| R&D expenses: | USD 6'758.96M | |
| Cash: | USD 7'815.74M | |
| No. of shares: | 982'424'082 | |
| Market cap. / valuation: | USD 43'695.46M | |